Literature DB >> 29242257

Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota.

Alexandra Zimmermann1, Henrik Knecht1, Robert Häsler1, Gernot Zissel2, Karoline I Gaede3,4, Sylvia Hofmann5, Almut Nebel1, Joachim Müller-Quernheim2, Stefan Schreiber1,6, Annegret Fischer7.   

Abstract

Sarcoidosis is a granulomatous disease that mainly affects the lung. A role of microbial factors in disease pathogenesis is assumed, but has not been investigated systematically in a large cohort.This cross-sectional study compared the lung microbiota of 71 patients with sarcoidosis, 15 patients with idiopathic pulmonary fibrosis (non-infectious controls) and 10 healthy controls (HCs). Next-generation sequencing of 16S DNA was used on bronchoalveolar lavage samples to characterise the microbial composition, which was analysed for diversity and indicator species. Host genotypes for 13 known sarcoidosis risk variants were determined and correlated with microbial parameters.The microbial composition differed significantly between sarcoidosis and HC samples (redundancy analysis ANOVA, p=0.025) and between radiographic Scadding types. Atopobium spp. was detected in 68% of sarcoidosis samples, but not in HC samples. Fusobacterium spp. was significantly more abundant in sarcoidosis samples compared with those from HCs. Mycobacteria were found in two of 71 sarcoidosis samples. Host-genotype analysis revealed an association of the rs2076530 (BTNL2) risk allele with a decrease in bacterial burden (p=0.002).Our results indicate Scadding type-dependent microbiota in sarcoidosis BAL samples. Atopobium spp. and Fusobacterium spp. were identified as sarcoidosis-associated bacteria, which may enable new insights into the pathogenesis and treatment of the disease.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29242257     DOI: 10.1183/13993003.00746-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

Review 1.  Molecular profiling in sarcoidosis.

Authors:  Nicholas K Arger; Brian O'Connor; Laura L Koth
Journal:  Curr Opin Pulm Med       Date:  2020-09       Impact factor: 3.155

2.  The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis.

Authors:  Kristel S Knudsen; Sverre Lehmann; Rune Nielsen; Solveig Tangedal; Andreu Paytuvi-Gallart; Walter Sanseverino; Einar M H Martinsen; Pieter S Hiemstra; Tomas M Eagan
Journal:  Microbiome       Date:  2022-10-19       Impact factor: 16.837

3.  Low IgA Associated With Oropharyngeal Microbiota Changes and Lung Disease in Primary Antibody Deficiency.

Authors:  Roos-Marijn Berbers; Firdaus A A Mohamed Hoesein; Pauline M Ellerbroek; Joris M van Montfrans; Virgil A S H Dalm; P Martin van Hagen; Fernanda L Paganelli; Marco C Viveen; Malbert R C Rogers; Pim A de Jong; Hae-Won Uh; Rob J L Willems; Helen L Leavis
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 4.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity.

Authors:  Amy Proal; Trevor Marshall
Journal:  Front Pediatr       Date:  2018-12-04       Impact factor: 3.418

Review 5.  Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.

Authors:  Pleiades T Inaoka; Masato Shono; Mishio Kamada; J Luis Espinoza
Journal:  J Biomed Sci       Date:  2019-06-11       Impact factor: 8.410

6.  A common microbial signature is present in the lower airways of interstitial lung diseases including sarcoidosis.

Authors:  Valeria D'Argenio; Giorgio Casaburi; Vincenza Precone; Livio Gioacchino Moccia; Irene Postiglione; Marialuisa Bocchino; Alessandro Sanduzzi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-09       Impact factor: 0.670

Review 7.  Role of the Microbiome in Interstitial Lung Diseases.

Authors:  Ozioma S Chioma; Laura E Hesse; Austin Chapman; Wonder P Drake
Journal:  Front Med (Lausanne)       Date:  2021-01-28

8.  Comparative analysis of the alveolar microbiome in COPD, ECOPD, Sarcoidosis, and ILD patients to identify respiratory illnesses specific microbial signatures.

Authors:  Shashank Gupta; Malini Shariff; Gaura Chaturvedi; Agrima Sharma; Nitin Goel; Monika Yadav; Martin S Mortensen; Søren J Sørensen; Mitali Mukerji; Nar Singh Chauhan
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

9.  Association Between Serum Thyroid-Stimulating Hormone Levels and Salivary Microbiome Shifts.

Authors:  Ting Dong; Fen Zhao; Keyong Yuan; Xiaohan Zhu; Ningjian Wang; Fangzhen Xia; Yingli Lu; Zhengwei Huang
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

Review 10.  Environmental Risk Factors for Sarcoidosis.

Authors:  Marc A Judson
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.